- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | UK says it has hit target on commercial trial set-up times | ||
| Do | Lift for UK healthtech as fund bags £100m from national bank | ||
| Do | FDA accelerated approval path needs improvement, says ICER | ||
| Do | Lilly says Foundayo safety confirmed in ACHIEVE-4 trial | ||
| Do | Beeline raises $300m for BMS drugs, and other biofinancings | ||
| Do | Most patients "won't see benefit" with Alzheimer's drugs | ||
| Mi | Novartis CEO joins board of "responsible" AI firm Anthropic | ||
| Mi | Scientists issue call to arms over antifungal resistance | ||
| Mi | Daiichi exits OTC, with $1.55bn unit sale to Suntory | ||
| Mi | Parkinson's charity partners Biognosys on biomarker project | ||
| Mi | Amazon launches its AI drug discovery platform | ||
| Mi | FDA seeks safety data for Lilly's oral GLP-1 Foundayo | ||
| Di | FDA renews criticism of trial sponsors over transparency | ||
| Di | Novo Nordisk partners OpenAI on R&D "transformation" | ||
| Di | Travere claims first FDA OK in rare kidney disease FSGS | ||
| Di | Revolution rockets on strong pancreatic cancer data | ||
| Di | Alamar, Hemab, Kailera, and Seaport advance IPOs | ||
| Mo | IDEAYA/Servier PKC drug aces uveal melanoma trial | ||
| Mo | AI could spare bowel cancer patients from unneeded treatment | ||
| Mo | NICE update doubles eligible patients for AZ's Lokelma | ||
| Mo | Data backs GSK's ovarian cancer blockbuster hopes | ||
| Mo | FDA hands another rejection to Replimune's melanoma therapy | ||
| 10.04. | Senju launches first-in-class dry eye disease drug in Japan | ||
| 10.04. | Diagnostics lag is holding back new therapies, says study | ||
| 10.04. | Chinese trial backs base-editing drug for thalassaemia |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.